340B ‘Penny Pricing’ Policy Formally Adopted By HHS; Overcharging Safe Harbors Created
Executive Summary
Final rule on 340B discounts also addresses how to handle pricing for new drugs.
You may also be interested in...
340B Penny Pricing, Civil Monetary Penalty Revisions On Deck In Proposed Rule
Proposed rule will revisit controversial provisions in the January 340B final rule to address manufacturer concerns about the US discount program.
340B Pricing, Penalty Alternatives Will Be Reassessed; Final Rule Delayed
Pharma pushback pays off as HRSA requests additional public comment on key issues, including 340B ceiling prices and manufacturer civil monetary penalties.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.